Search PubMed⌕ Search

Biomedical subjects

Lawrence D True

Publications and source records attributed to Lawrence D True.

28 records · Page 2Linked to original sources
PubMed2003

Fatal Bacillus cereus sepsis following resolving neutropenic enterocolitis during the treatment of acute leukemia.

Bacillus cereus is increasingly being acknowledged as a serious bacterial pathogen in immunosuppressed hosts. We report a case of fatal B. cereus sepsis in a patient with newly diagnosed acute leukemia following resolving neutropenic enterocolitis. Gastrointestinal complaints are common during induction chemotherapy, yet some antimicrobial coverage suitable for generalized neutropenia is not optimal for the eradication of B. cereus. This case demonstrates that, in the neutropenic patient with gastrointestinal complaints or in the setting of resolving neutropenic enterocolitis, it is important to anticipate possible B. cereus infection and sepsis.

Adult↗
PubMed2003

Flow cytometry analysis of proliferative lesions at the gastrocystoplasty anastomosis.

PURPOSE: Proliferative epithelial metaplasia that develops in the anastomotic line after gastrocystoplasty has unknown malignant potential. Flow cytometry analysis of cell cycle profiles is used to predict the neoplastic progression of metaplastic lesions in other proliferative epithelium. We used this technique to evaluate transitional cell metaplasia in rat gastrocystoplasty specimens. MATERIALS AND METHODS: A total of 50 prepubescent female Long-Evans rats were randomly assigned to an experimental group (gastrocystoplasty) or a control group (sham operation). At 21 to 27 months (mean 24.9) after operation 12 rats per group survived to sacrifice. Metaplastic lesions were microdissected to yield a minimum of 10(4) cells for DNA flow cytometry and cell cycle analysis. Transitional cell epithelium from sham specimens and gastric epithelium from experimental animals served as controls. RESULTS: Transitional cell hyperplasia and metaplasia with cyst formation were found in the anastomotic line in all 12 augmented bladders (100%). No proliferative lesions developed in control animals. No nuclear pleomorphism or mitotic changes were identified on routine histological examination. The epithelial cell turnover rate was 10 times higher in the gastrocystoplasty junctional zone than in control bladders (mean 2.2% versus 0.1% S phase) but lower than in native stomach epithelium (mean 3.3% S phase). Of 12 experimental specimens 1 showed near diploid DNA aneuploidy. No DNA abnormalities were detected in control bladder or stomach specimens. CONCLUSIONS: In this animal model histologically benign appearing proliferative lesions that develop in the anastomotic zone after long-term gastrocystoplasty harbor cell cycle and DNA ploidy abnormalities.

Anastomosis, Surgical↗
PubMed2003

Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone.

To better understand the clinical and pathologic features of end-stage, androgen-independent carcinoma of the prostate (CaP), we performed rapid autopsies on 14 men who died of progressive CaP and recorded relevant clinical data. The timing of tumor progression varied widely. The median time to androgen independence was 2 years (range, 4 months to 13.6 years). The median survival after androgen independence was 1 year (range, 1 month to 3.6 years). Because osseous metastases are prevalent in progressive CaP, up to 20 bone sites were systematically sampled in each patient. Bone metastases were widespread; tumor filled the marrow in an average of 14 bone sites. Tumor histology and expression of prostate-specific antigen (PSA) and chromogranin A (CGA) were examined in all metastases and were compared with the primary tumor. Five histological patterns of metastatic tumor were observed: solid (10 patients), macroacinar (1 patient), microacinar (1 patient), clear cell (1 patient), and comedocarcinoma (1 patient). Gleason grade of the primary tumor did not predict the histological pattern of the metastases. Although >70% of tumor cells expressed PSA, the fraction of PSA-positive cells varied widely in separate metastases in some patients (standard deviation >25). Likewise, the fraction of neuroendocrine (NE) (CGA-positive) tumor cells in different metastases varied widely. For example, between 0 and 95% of tumor cells in different metastases in 1 patient had a NE phenotype. The present study highlights the heterogeneity--histologically and immunophenotypically--of metastatic CaP. Consequently, therapy directed to the phenotype of 1 metastasis may have no effect on other metastases in the same patient because of phenotypic heterogeneity.

Adenocarcinoma↗
PubMed2003

Isolation and characterization of human and mouse WDR19,a novel WD-repeat protein exhibiting androgen-regulated expression in prostate epithelium.

Androgens regulate important processes involved in the normal development and function of the human and rodent prostate glands. Here we report the isolation and characterization of a new androgen-regulated gene, designated WDR19, that encodes repeating sequence motifs found in the WD-repeat family of proteins. The WD repeat is a conserved domain of approximately 40 amino acids that is typically bracketed by glycine-histidine and tryptophan-aspartic acid (WD) dipeptides. WD-repeat proteins are a large group of structurally related proteins that participate in a wide range of cellular functions, including transmembrane signaling, mRNA modification, vesicle formation, and vesicular trafficking. The WDR19 gene comprises 36 exons and is located on chromosome 4p15-4p11. The predicted protein contains six WD repeats, a clathrin heavy-chain repeat, and three transmembrane domains. Sequence analysis reveals that the WDR19 gene is conserved from Caenorhabditis elegans to human. WDR19 is expressed in normal and neoplastic prostate epithelium as demonstrated by RNA in situ hybridization and is regulated by androgenic hormones. WDR19 transcripts exhibit alternative splicing in which two isoforms appear to be prostate restricted, a property that could be exploited for designing diagnostic or therapeutic strategies for prostate carcinoma.

Alternative Splicing↗
PubMed2002

Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.

Disruption of the TSC1 or TSC2 gene leads to the development of tumors in multiple organs, most commonly affecting the kidney, brain, lung, and heart. Recent genetic and biochemical studies have identified a role for the tuberous sclerosis gene products in phosphoinositide 3-kinase signaling. On growth factor stimulation, tuberin, the TSC2 protein, is phosphorylated by Akt, thereby releasing its inhibitory effects on p70S6K. Here we demonstrate that primary tumors from tuberous sclerosis complex (TSC) patients and the Eker rat model of TSC expressed elevated levels of phosphorylated mammalian target of rapamycin (mTOR) and its effectors: p70S6K, S6 ribosomal protein, 4E-BP1, and eIF4G. In the Eker rat, short-term inhibition of mTOR by rapamycin was associated with a significant tumor response, including induction of apoptosis and reduction in cell proliferation. Surprisingly, these changes were not accompanied by significant alteration in cyclin D1 and p27 levels. Our data provide in vivo evidence that the mTOR pathway is aberrantly activated in TSC renal pathology and that treatment with rapamycin appears effective in the preclinical setting.

Animals↗
PubMed2002

A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49.

The late stages of progression of prostate carcinoma are typically characterized by an androgen-insensitive, rapidly proliferative state. Some late-stage tumors are composed predominantly of neuroendocrine cells. Virtually no animal models of a neuroendocrine/small cell variant of prostate carcinoma are available for experimental studies. We report a human neuroendocrine/small cell prostate carcinoma xenograft that was developed from a nodal metastasis of a human prostate carcinoma and that has been propagated as serial subcutaneous implants in severe combined immunodeficient mice for >4 years. Designated LuCaP 49, all tumor passages exhibit a neuroendocrine/small cell carcinoma phenotype-insensitivity to androgen deprivation, expression of neuroendocrine proteins, lack of expression of prostate-specific antigen or androgen receptor, and an unusually rapid growth (a doubling time of 6.5 days) for prostate cancer xenografts. Genetically this tumor exhibits loss of heterozygosity for the short arm of chromosome 8 and has a complex karyotype. This xenograft should prove to be useful in the investigation of mechanisms underlying the androgen-insensitive state of progressive prostate carcinoma.

Aged↗
PubMed2002

Characterization of prostate cell types by CD cell surface molecules.

A set of monoclonal antibodies raised against lymphocyte cell surface molecules, the cluster designation (CD) antigens, was used to distinguish the constituent cell types of the prostate. The luminal secretory epithelial, basal epithelial, fibromuscular stromal, nerve sheath, and endothelial cells express distinctive complements of cell surface molecules that were identified by immunohistochemistry using 152 commercially available antibodies. Many of the CD antibodies stained lymphocyte populations in the prostate. These lymphocyte populations were grouped into abundance classes of rare, moderate, and high. Some of these molecules are expressed by multiple cell types, both parenchymal and lymphoid; others are expressed by only one cell type. Distinctive patterns of CD expression, which are most similar to the expression pattern of prostate luminal cells, also characterize a small series of Gleason score 6 prostate cancers. The cell-type specificity of CD molecules increases the prospect of isolating specific cell populations, using such techniques as laser capture microdissection and flow cytometry, for cell-specific molecular studies.

Adenocarcinoma↗